דואביב
pfizer pfe pharmaceuticals israel ltd - bazedoxifene acetate; estrogens conjugated - טבליות בשחרור מושהה - bazedoxifene acetate 20 mg; estrogens conjugated 0.45 mg - conjugated estrogens and bazedoxifene
אסטרוגנוס ® 0.9 מ"ג
salomon,levin & elstein ltd - estrogens conjugated 0.9 mg - tablets - conjugated estrogens - estrogenus tablets are indicated in the:treatment of moderate to severe vasomotor symptoms associated with menopause.
אסטרוגנוס ® 0.3 מ"ג
salomon,levin & elstein ltd - estrogens conjugated 0.3 mg - tablets - conjugated estrogens - estrogenus tablets are indicated in the:1. treatment of moderate to severe vasomotor symptoms associated with menopause. 2. treatment of moderate to severe vaginal dryness and pain with intercourse, symptoms of vulvar and vaginal atrophy, associated with menopause. when prescribing solely for the treatment of moderate to severe vaginal dryness and pain with intercourse, topical vaginal products should be considered.
אסטרוגנוס ® 0.45 מ"ג
salomon,levin & elstein ltd - estrogens conjugated 0.45 mg - tablets - conjugated estrogens - estrogenus tablets are indicated in the:treatment of moderate to severe vasomotor symptoms associated with menopause.
אסטרוגנוס ® 0.625 מ"ג
salomon,levin & elstein ltd - estrogens conjugated 0.625 mg - tablets - conjugated estrogens - estrogenus tablets are indicated in the:treatment of moderate to severe vasomotor symptoms associated with menopause.
אסטרוגנוס ® 1.25 מ"ג
salomon,levin & elstein ltd - estrogens conjugated 1.25 mg - tablets - conjugated estrogens - estrogenus tablets are indicated in the:treatment of moderate to severe vasomotor symptoms associated with menopause.
ארומזין
pfizer pfe pharmaceuticals israel ltd - exemestane - טבליות מצופות - exemestane 25 mg - exemestane - exemestane - aromasin is indicated for the treatment of advanced breast cancer (abc) in women with natural or induced postmenopausal status whose disease has progressed following anti-oestrogen therapy alone. aromasin is also indicated for the treatment of postmenopausal women with abc whose disease has progressed following multiple hormonal therapies. aromasin is indicated for the adjuvant treatment of postmenopausal women with oestrogen receptor positive invasive early breas cancer following 2-3 years of initial adjuvant tamoxifen therapy.
פרימולוט-נור
bayer israel ltd - norethisterone acetate - טבליה - norethisterone acetate 5 mg - norethisterone - norethisterone - oral progestron for: dysfunctional bleeding, primary and secondary amenorrhea, premenstrual syndrome, timing of mensturation and endometriosis.
קונבריזה
neopharm ltd - bazedoxifene as acetate 20 mg - coated tablets - bazedoxifene - conbriza is indicated for the treatment of postmenopausal osteoporosis in women at increased risk of fracture. a significant reduction in the incidence of vertebral fractures has been demonstrated; efficacy on hip fractures has not been established. when determining the choice of conbriza or other therapies, including oestrogens, for an individual postmenopausal woman, consideration should be given to menopausal symptoms, effects on uterine and breast tissues, and cardiovascular risks and benefit
מיקרוגינון 30
bayer israel ltd - ethinylestradiol; levonorgestrel - טבליות מצופות - levonorgestrel 150 mcg; ethinylestradiol 30 mcg - progestogens and estrogens, fixed combinations - oral contraceptive.